Your new online monitoring tool!
Monday, October 3, 2022SCCS

Genistein, Daidzein: final Opinion of the SCCS

Genistein, Daidzein : Opinion finale du CSSC

Following the mandate given by the European Commission to the SCCS in the context of the safety assessment of substances with potential endocrine disrupting properties, the Scientific Committee has just published its final Opinion on Genistein and Daidzein. It was adopted by written procedure on 16 September 2022.

Reading time
~ 3 minutes


Phytoestrogens are plant-derived compounds with structural similarity to 17β-estradiol, the primary female sex hormone. Among the phenolic compounds classified as phytoestrogens are isoflavones.
Among the most common isoflavones are Genistein (CAS No.446-72-0, EC No.207-174-9) and Daidzein (CAS No.486-66-8, EC No.207-635-4).
Currently, Genistein and Daidzein are not regulated under the Cosmetic Regulation (EC) No.1223/2009.
The Scientific Committee issued its preliminary Opinion in January 2022, with a favourable opinion for Genistein (at 0.007%) and an unfavourable opinion for Daidzein.

For an exhaustive background information, see the articles
Endocrine disruptors: 2nd call for data from the European Commission, CosmeticOBS, 22 February 2021
Endocrine disruptors: 5 new requests for SCCS Opinions, CosmeticOBS, 15 March 2021
Genistein, Daidzein: preliminary Opinion of the SCCS, CosmeticOBS, 17 January 2022

This Opinion has been subject to a commenting period of eight weeks after its initial publication (from 13 January to 14 March 2022). Comments received during this period were considered by the SCCS. For this Opinion, the main changes were in the section 3.3.6. mutagenicity and genotoxicity, as well as relevant parts in the discussion, conclusion and reference sections.

Final Opinion

1. In light of the data provided and taking under …

This content is only available to subscribersPREMIUM, PRO, STARTUP and TPE

Already subscribed?Log in

Discover our subscriptions

CosmeticOBS' PRO services

SCCSOther articles